Interleukin 23 regulates proliferation of lung cancer cells in a concentration-dependent way in association with the interleukin-23 receptor

Carcinogenesis

Volumn 34, Issue 3, 2013, Pages 658-666

  Li, Jun ^a   Zhang, Le ^a   Zhang, Jie ^a   Wei, Yuyan ^a   Li, Kai ^a   Huang, Lugang ^a   Zhang, Sen ^a   Gao, Bo ^a   Wang, Xiujie ^a   Lin, Ping ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; KI 67 ANTIGEN; RECEPTOR SUBUNIT; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER TISSUE; CELL GROWTH; CELL PROLIFERATION; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING;

ADENOCARCINOMA; AGED; ANIMALS; CARCINOMA, SMALL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INTERLEUKIN-23; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-12; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR BURDEN;

EID: 84874773199     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs384     Document Type: Article

References (43)

1. Jemal, A. et al. (2008) Cancer statistics, 2008. CA. Cancer J. Clin., 58, 71-96.
2. Sorrentino, C. et al. (2009) Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. Am. J. Respir. Crit. Care Med., 180, 769-779.
3. Yamaguchi, T. et al. (1998) Involvement of interleukin-6 in the elevation of plasma fibrinogen levels in lung cancer patients. Jpn. J. Clin. Oncol., 28, 740-744.
4. Behrens, C. et al. (2010) Expression of interleukin-1 receptor-associated kinase-1 in non-small cell lung carcinoma and preneoplastic lesions. Clin. Cancer Res., 16, 34-44.
5. Moreira, A.P. et al. (2011) The protective role of TLR6 in a mouse model of asthma is mediated by IL-23 and IL-17A. J. Clin. Invest., 121, 4420-4432.
6. Oppmann, B. et al. (2000) Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity, 13, 715-725.
7. Brunda, M.J. et al. (1993) Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med., 178, 1223-1230.
8. Nastala, C.L. et al. (1994) Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J. Immunol., 153, 1697-1706.
9. Cua, D.J. et al. (2003) Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature, 421, 744-748.
10. Murphy, C.A. et al. (2003) Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med., 198, 1951-1957.
11. Becher, B. et al. (2003) IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J. Clin. Invest., 112, 1186-1191.
12. Oniki, S. et al. (2006) Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res., 66, 6395-6404.
13. Lo, C.H. et al. (2003) Antitumor and antimetastatic activity of IL-23. J. Immunol., 171, 600-607.
14. Wang, Y.Q. et al. (2003) Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells. Int. J. Cancer, 105, 820-824.
15. Langowski, J.L. et al. (2006) IL-23 promotes tumour incidence and growth. Nature, 442, 461-465.
16. Piskin, G. et al. (2006) In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J. Immunol., 176, 1908-1915.
17. Lan, F. et al. (2010) IL-23/IL-23R: potential mediator of intestinal tumor progression from adenomatous polyps to colorectal carcinoma. Int. J. Colorectal Dis., 26, 1511-1518.
18. Cocco, C. et al. (2010) Interleukin-23 acts as antitumor agent on childhood B-acute lymphoblastic leukemia cells. Blood, 116, 3887-3898.
19. Fukuda, M. et al. (2010) IL-23 promotes growth and proliferation in human squamous cell carcinoma of the oral cavity. Int. J. Oncol., 36, 1355-1365.
20. Allred, D.C. et al. (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol., 11, 155-168.
21. Parham, C. et al. (2002) A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J. Immunol., 168, 5699-5708.
22. Presky, D.H. et al. (1996) A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc. Natl. Acad. Sci. U.S.A., 93, 14002-14007.
23. Walker, S.R. et al. (2010) Microtubule-targeted chemotherapeutic agents inhibit signal transducer and activator of transcription 3 (STAT3) signaling. Mol. Pharmacol., 78, 903-908.
24. Lin, L. et al. (2010) A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells. Mol Cancer, 16, 9-217.
25. Yen, D. et al. (2006) IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest., 116, 1310-1316.
26. Hill, H.C. et al. (2002) Cancer immunotherapy with interleukin 12 and granulocyte - macrophage colony-stimulating factor-encapsulated microspheres coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res., 62, 7254-7263.
27. Teng, M.W. et al. (2010) IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. Proc. Natl. Acad. Sci. U.S.A., 107, 8328-8333.
28. Teng, M.W. et al. (2011) Anti-IL-23 monoclonal antibody synergizes in combination with targeted therapies or IL-2 to suppress tumor growth and metastases. Cancer Res., 71, 2077-2086.
29. Trinchieri, G. et al. (2003) The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity, 19, 641-644.
30. Brivanlou, A.H. et al. (2002) Signal transduction and the control of gene expression. Science, 295, 813-818.
31. Gee, K. et al. (2009) The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm. Allergy Drug Targets, 8, 40-52.
32. O'Shea, J.J. et al. (2011) Genomic views of STAT function in CD4+ T helper cell differentiation. Nat. Rev. Immunol., 11, 239-250.
33. Bromberg, J. et al. (2000) The role of STATs in transcriptional control and their impact on cellular function. Oncogene, 19, 2468-2473.
34. Yamashita, S. et al. (2011) Ki-67 labeling index is associated with recurrence after segmentectomy under video-assisted thoracoscopic surgery in stage I non-small cell lung cancer. Ann. Thorac. Cardiovasc. Surg., 17, 341-346.
35. Yang, S.F. et al. (2005) The role of p-STAT3 (ser727) revealed by its association with Ki-67 in cervical intraepithelial neoplasia. Gynecol. Oncol., 98, 446-452.
36. Wang, H. et al. (2012) VEGF-mediated STAT3 activation inhibits retinal vascularization by down-regulating local erythropoietin expression. Am. J. Pathol., 180, 1243-1253.
37. Liu, Y. et al. (2011) Blocking the IL-6-STAT3 signaling pathway: potential liver cancer therapy. Future Oncol., 7, 161-164.
38. Pupjalis, D. et al. (2011) Annexin A1 released from apoptotic cells acts through formyl peptide receptors to dampen inflammatory monocyte activation via JAK/STAT/SOCS signalling. EMBO Mol. Med., 3, 102-114.
39. Chen, Z. et al. (2006) Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc. Natl. Acad. Sci. U.S.A., 103, 8137-8142.
40. Colombo, M.P. et al. (2002) Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev., 13, 155-168.
41. Yoshida, Y. et al. (2000) Impaired tumorigenicity of human pancreatic cancer cells retrovirally transduced with interleukin-12 or interleukin-15 gene. Cancer Gene Ther., 7, 324-331.
42. Boggio, K. et al. (1998) Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J. Exp. Med., 188, 589-596.
43. Leonard, L.P. et al. (1997) Effect of singledose interleukin-12 exposure on interleukin-12-associted toxicity and interferon-γ production. Blood, 90, 2541-2548.